OTCQB:PTLF



Request Offering Information

Click here to load this Caspio Cloud Database


Thank you for visiting the PetLife Pharmaceuticals, Inc. Investor Relations and Information page. We are currently updating our website and will provide a secure access section for investors and the public sections for information and data. Any questions, please CLICK HERE

1 844 4 PETLIFE
(844) 473-8543
info@petlifelifepharma.com



PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

LEGAL COUNSEL
Lance Brunson, Esq., of Brunson Chandler & Jones PLLC (“BCJ”)
175 S. Main Street, Suite 1410, Salt Lake City, Utah 84111

Independent Accountant
LBB & Associates Ltd., LLP
10260 Westheimer Road, Suite 310, Houston, Texas 77042

Transfer Agent
Empire Stock Transfer

Press Release Information

PetLife Pharmaceuticals Announces Haiti Veterinary Initiative

HANCOCK, MDOctober 19, 2017 — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, through its subsidiary, PetLife Pharma International, Inc. (collectively “PetLife”), and in cooperation with Elite International Partners (“Elite”), announces its initiatives in Haiti to improve the lives of companion animals and the people of Haiti. With the cooperation and support of the Haitian government, and in partnership with the Mission Light of Light Church, PetLife is establishing a scorpion ranch and laboratory facilities (“PetLife Scorpion Ranch™), to harvest the venom of the Caribbean Blue Scorpion. This effort will provide the necessary material for PetLife’s research efforts and production of its patent pending formulation for the treatment of cancer in animals and humans.

PetLife’s formulation has been developed to address a leading cause of death in companion animals, one that causes death of 47% of dogs and 32% of cats in the United States. We anticipate that a successful clinical trial in animals will not only relieve suffering in our companion pets but also will be the foundation for treatment of select human cancers. PetLife plans to proceed with the development of human applications after completion of our clinical and regulatory program which will be presented to the Food and Drug Administration (“FDA”) for approval soon. Once the program has been approved for implementation, PetLife anticipates that it will take approximately 24 months for the studies necessary for approval of the new animal drug which has been trademarked as VitalzulTM.

Our CEO, Dr. Ralph Salvagno, an Orthopaedic Surgeon, was part of the early medical teams that cared for victims of the earthquake in 2010. Returning several times since, he recognized the need for sustainable economic growth. PetLife is pleased to be part of the revitalization of the country of Haiti. As part of our new presence in Haiti, we are hosting a veterinary event with the aim of reducing the rapid spread of rabies in Haiti, which is the result of the earthquake. Haiti has the highest rate of human rabies deaths in the western hemisphere.

PetLife is working with the Mission Light of Light Church and the Haitian Government to establish a charitable foundation to benefit the orphans, workers and families who live nearby to our PetLife Scorpion Ranch™ and laboratory. As part of our long-term plan, we hope to establish a school, living quarters and medical facilities to the impoverished area.

About PetLife Pharmaceuticals

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company.  PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life.  The Company’s first product, Vitalzul™, is currently in testing.  Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines.  In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.  PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will launch in 2017.  PetLife Scorpion Ranch™ will break ground in 2017.  PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.   Company Contact Dr. Ralph Salvagno RSalvagno@PetLifePharma.com 844-473-8543 ext. 702

PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff's by PetLife, Preparing for Regional Launch

Press Release (ePRNews.com) - Hancock, MD - Jun 06, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that its wholly owned subsidiary, Dr. Geoff’s by PetLife, Inc. (“Dr. Geoff’s by PetLife”), PetLife’s product line of natural pet food, supplements, and treats, has initiated its comprehensive product rollout.

The Company, through its wholly owned subsidiary, will proceed with an initial regional pilot launch, followed by a national rollout. The introductory product launch will focus on two Superfood Supplements: ImmunoPower™ and Antioxidant Boost™, and several canned food products, with extensive plans for product line expansion.

ImmunoPower™ is a unique, proprietary blend of micro-ingredients that equips the pet’s body with the nutrients to support overall well-being and is formulated to deliver as much antioxidant power as possible.

Antioxidant Boost™ uses the power of antioxidant vitamins, antioxidant chelated minerals, phytonutrients, digestive enzymes and probiotics combined in this unique super-food.

The TV commercial for the product launch has been prepared and completed by a world-class production and media team. Media buys are currently being sourced to provide the best value. For a short segment view of the TV commercial, visit: http://www.petlifepharma.com/drg/. This TV commercial will be incorporated into an infomercial and promoted through social media.

“The strategic advantage of launching our food product in advance of the anticipated FDA approved Vitalzul™ is that it provides the Company the advantage of revenues, profits and enhanced cash flow,” stated Dr. Ralph Salvagno, CEO of PetLife. “Brand awareness is a key component for success given the competitive market in the pet food industry. We believe that our core product, Vitalzul™, when infused into pet food, will create an extraordinary, proprietary and world class product for pets and their owners. The Company plans to offer two additional food products infused with Vitalzul™: a veterinary prescribed, therapeutic form for pets with cancer, and a product proposed as a preventive for older dogs. Statistically, 49% of dogs and 38% of cats will be stricken with some form of cancer after the age of 10.”

PetLife plans to roll out a complete line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products for dogs and cats. PetLife is in discussions with third parties to provide specific complementary products that would not be “just another product on the shelf” but those that have proprietary properties that will enhance PetLife’s reputation as a quality provider of natural-based solutions for animal diseases and conditions.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, is launching in 2017. PetLife Scorpion Ranch™ is breaking ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:

This press release contains certain “forward-looking statements,” as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Clifford Price
clifford@petlifepharma.com
844-473-8543 ext. 701
June 1, 2017
PetLife Pharmaceuticals Launches New Website
HANCOCK, MD / May 30, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company,” “PetLife”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced its new Website, www.petlifepharma.com.
View Release

May 30, 2017
PetLife Files for Patent for the Treatment of Cancer for Pets
Combining Chlorotoxin and Plant-based Therapeutics in an Advanced Formulation with New Technology
HANCOCK, MD—May 30, 2017—PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that we have filed for patent protection in India and the United States for the formula for Vitalzul™.
View Release

May 28, 2017
PetLife Management Comments on Recent Market Activity
By AccessWire, May 28, 2017, 02:00:00 AM EDT
HANCOCK, MD / ACCESSWIRE / May 28, 2017 /PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company," "We"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced the Company's comments on recent developments in its stock price and trading performance.
View Release

May 26, 2017
PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line
By AccessWire, May 26, 2017, 06:00:00 AM EDT
HANCOCK, MD / ACCESSWIRE / May 26, 2017 /PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they are exploring various new products for their product line.
View Release

May 23, 2017
PetLife Closes Acquisition of Assets for Dr. Geoff's Real Food for Pets
The product line is projected to include VitalZul™ in a second generation of the product in 2018
HANCOCK, MD / ACCESSWIRE / May 23, 2017 / PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that its subsidiary, Dr. Geoff's by PetLife, Inc. ("Dr. Geoff's by PetLife"), has completed the acquisition of assets related to the natural pet food product line.
View Release

May 16, 2017
PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application
Press Release (ePRNews.com) - Hancock, Maryland - May 16, 2017 - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has engaged Carter, Terry & Company (“Carter Terry”), a full-service investment brokerage, investing banking, asset management, and banking services firm, to help finance the development of PetLife’s product development and research to fight cancer in pets and the FDA application. The Company seeks to raise $4 million in this series of financing.
View Release

April 18, 2017
PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets
HANCOCK, Md.--(BUSINESS WIRE)--
PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that it has finalized the negotiations for the acquisition of Dr. Geoff’s Real Food for Pets™. The closing of the acquisition of the trademarked brands and the natural pet food product line is projected to occur within two weeks. VIEW PR

April 12, 2017
PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine
Business Wire
HANCOCK, Md.--(BUSINESS WIRE)--
PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the current state of holistic pet health practices in veterinary medicine. VIEW RELEASE

March 21, 2017
PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets
March 21, 2017 07:00 AM Eastern Daylight Time
HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has proceeded to the next expected stage of acquiring Dr. Geoff’s Real Food for Pets™ and simultaneously has expanded plans for a national rollout.
VIEW PRESS RELEASE

March 7, 2017
PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry - HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the $63 billion companion pet healthcare industry. Empty nesters, reduced fertility, and pet owners prioritizing pet care over their own expenses all contribute to the resiliency of the pet care industry. PetLife’s continuous development of multiple product lines aims to serve the growing companion pet healthcare market, bolstering its market reach and thereby solidifying the company both on a revenue/financial point of view as a natural, solution-focused company.
VIEW PRESS RELEASE

February 28, 2017
PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand - HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it signed a Letter of Intent to acquire the assets of Healthy Life Pets. Most commonly known as Dr. Geoff’s Real Food for Pets™, assets in this brand include six SKUs of retail-ready products, including both canned food and antioxidant supplements.
VIEW PRESS RELEASES

February 20, 2017

PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba- HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
VIEW PRESS RELEASES

February 10, 2017
World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board - Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry.
VIEW PRESS RELEASES

January 10, 2017
PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
VIEW PRESS RELEASES

December 7, 2016
PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
VIEW PRESS RELEASES

December 6, 2016
PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission
VIEW PRESS RELEASES

December 1, 2016
PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings
VIEW PRESS RELEASES

November 15, 2016
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
VIEW PRESS RELEASES

October 27, 2016
PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline
VIEW PRESS RELEASES

October 24, 2016
PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
VIEW PRESS RELEASES

October 19, 2016
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
VIEW PRESS RELEASES

Press Release May 30, 2017

PetLife Files for Patent for the Treatment of Cancer for Pets
Combining Chlorotoxin and Plant-based Therapeutics in an Advanced Formulation with New Technology

HANCOCK, MD—May 30, 2017—PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that we have filed for patent protection in India and the United States for the formula for Vitalzul™.

The Company, through an officer of the Company, has filed for a patent in India titled A Composition for Targeting Cancer in Canines and Humans. The patent protection is for both process and composition thus protecting not only the physical elements of our formulation but also the process by which they are combined. This new patent pending advanced formulation will be the basis for PetLife’s product, Vitalzul™, for the proposed treatment of certain cancers in dogs and cats. The human application and opportunity will be discussed at a later date as the Company continues to expand its long-term plan.

The filing in the United States was titled the same as the India patent with the same attributes as filed in India.

The elements of the formulation of Vitalzul™ have been shown to have extremely minimal toxicity. The components of the formulation are natural, not synthetic.

Dr. Ralph Salvagno, CEO of PetLife, stated, “Our team of scientists and researchers in India and in the U.S. have worked diligently to bring an advanced version of Vitalzul™ to the next stage of our growth plan. With the patents filed, we will continue the course towards our FDA application. The goal is to bring Vitalzul™ to market by the end of 2018.”

About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul’s™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s by PetLife™, will launch in 2017. PetLife anticipates incorporating VitalZul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact
Clifford Price
clifford@PetLifePharma.com
844-473-8543 ext. 701

SEC FILINGS

NOTE: IF YOU HAVE PROBLEMS OPENING FILES PLEASE VISIT

SEC.GOV PETLIFE UPDATED INFORMATION - CLICK HERE



Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-003868 (34 Act)  Size: 3 MB
2017-04-14 000-52445
17762868
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001477932-17-001629 (34 Act)  Size: 612 KB
2017-04-07 005-82533
17750104
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001493152-17-002852 Size: 14 KB
2017-03-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001493152-17-002849 Size: 13 KB
2017-03-24
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001493152-17-002847 Size: 3 KB
2017-03-24
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-001329 (34 Act)  Size: 1 MB
2017-02-10 000-52445
17593133
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-001329 (34 Act)  Size: 1 MB
2017-02-10 000-52445
17593133
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-17-001078 (34 Act)  Size: 26 KB
2017-02-03 000-52445
17570896
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-17-000431 (34 Act)  Size: 31 KB
2017-01-13 000-52445
17526460
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-016114 (34 Act)  Size: 2 MB
2016-12-21 000-52445
162064643
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Acc-no: 0001493152-16-015634 (34 Act)  Size: 30 KB
2016-12-05 000-52445
162032602
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-16-014213 (34 Act)  Size: 27 KB
2016-10-24 000-52445
161947776
8-K  Documents Current report, item 1.01
Acc-no: 0001493152-16-013223 (34 Act)  Size: 22 KB
2016-09-09 000-52445
161878940
8-K  Documents Current report, item 1.01
Acc-no: 0001493152-16-013094 (34 Act)  Size: 17 KB
2016-09-02 000-52445
161868796
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-011672 (34 Act)  Size: 784 KB
2016-07-21 000-52445
161777259
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-16-011563 (34 Act)  Size: 28 KB
2016-07-15 000-52445
161768982
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001074140-16-000002 Size: 3 KB
2016-06-22
D  Documents Notice of Exempt Offering of Securities, item 06c
Acc-no: 0001074140-16-000001 (33 Act)  Size: 6 KB
2016-06-22 021-265521
161725318
DEF 14C  Documents Other definitive information statements
Acc-no: 0001493152-16-010126 (34 Act)  Size: 56 KB
2016-05-20 000-52445
161664875
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-009048 (34 Act)  Size: 801 KB
2016-04-19 000-52445
161579733
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-16-008956 (34 Act)  Size: 28 KB
2016-04-15 000-52445
161574074
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-16-070262 Size: 36 KB
2016-03-30
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-008263 (34 Act)  Size: 62 KB
2016-03-25 000-52445
161528314
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-16-008259 (34 Act)  Size: 17 KB
2016-03-25 000-52445
161528227
CORRESP  Documents [Cover]Correspondence
Acc-no: 0001493152-16-008261 Size: 89 KB
2016-03-24
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-16-068777 Size: 163 KB
2016-03-17
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-006776 (34 Act)  Size: 937 KB
2016-01-14 000-52445
161342454
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006692 (34 Act)  Size: 30 KB
2016-01-08 000-52445
161332575
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006631 (34 Act)  Size: 1 MB
2016-01-06 000-52445
161325304
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006570 (34 Act)  Size: 1 MB
2016-01-05 000-52445
161319989
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006520 (34 Act)  Size: 974 KB
2015-12-31 000-52445
151316233
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006514 (34 Act)  Size: 947 KB
2015-12-31 000-52445
151316196
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006511 (34 Act)  Size: 975 KB
2015-12-31 000-52445
151316170
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-15-006481 (34 Act)  Size: 1 MB
2015-12-31 000-52445
151315440
8-K  Documents Current report, items 4.01 and 9.01
Acc-no: 0001493152-15-006412 (34 Act)  Size: 36 KB
2015-12-28 000-52445
151307906
NTN 10K  Documents Notices of Late Filings of Form 10-K or 10-KSB
Acc-no: 0001493152-15-005993 (34 Act)  Size: 30 KB
2015-12-02 000-52445
151263457
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-15-000011 (34 Act)  Size: 30 KB
2015-05-15 005-82533
15871144
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001360865-15-000001 (34 Act)  Size: 12 KB
2015-01-15 000-52445
15529432
10-K  Documents Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001360865-14-000061 (34 Act)  Size: 442 KB
2014-12-16 000-52445
141288078
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Acc-no: 0001360865-14-000059 (34 Act)  Size: 12 KB
2014-12-01 000-52445
141257550
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001360865-14-000053 Size: 3 KB
2014-10-03
8-K  Documents Current report, item 5.02
Acc-no: 0001360865-14-000052 (34 Act)  Size: 10 KB
2014-10-03 000-52445
141138909
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001360865-14-000051 Size: 3 KB
2014-09-29
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000050 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125941
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000049 (34 Act)  Size: 25 KB
2014-09-29 005-82533
141125929
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000048 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125913